Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Fr | Why We Need to Rethink Private Practice Mental Health Care | ||
Fr | The Truth About Portals: Why Is Patient Usage so Low? | ||
Fr | The Top-Ranked Private Cord Blood Banks in the U.S. | ||
Fr | AI in Healthcare: Investors' Green and Red Flags Among Startups | ||
Do | Roche's Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition | ||
Do | Why Insurers Need to Lead in the Shift to Healthcare Consumerism | ||
Do | What Self-Insured Employers Should Look for in a Digital Health Vendor | ||
Do | Behind "Rise of Malingering" in ER Psychiatry: Why Better Patient Classification Matters | ||
Do | Do You Value MedCity News? Take Our Survey! | ||
Do | Lovu Health Rakes In $8M for Maternal Health Platform | ||
Do | Inside Duke's Approach to Building and Buying AI Tools | ||
Mi | GSK Plans to Spend $30B on U.S. Manufacturing and R&D Infrastructure Over the Next 5 Years | ||
Mi | The Delegation Dilemma: Why It's Time for Health Plans to Rethink Vendor-Managed Utilization Management | ||
Mi | Addressing the Primary Care Crisis by Integrating Advanced Practice Providers (APPs) | ||
Mi | The Top EAP Companies for Mental Health Support | ||
Mi | Harbor Health Secures $130M To Grow Insurance Plans and Clinical Footprint | ||
Di | With Drug Picked Up From Sanofi, Startup AllRock Takes Aim at Two Severe Lung Diseases | ||
Di | Humans Make the Game: What Baseball's Tech Debate Can Teach Healthcare About the Value of Connection | ||
Di | How (and Where) to Find the Best Value Rehabilitation Programs for Brain Injuries | ||
Di | Obesity, Cancer, and the New Frontier of Treatment | ||
Di | Berry Street Introduces GLP-1 Nutrition Program | ||
Di | How HBO's Emmy-Winning Drama Captures the Chaos Hospitals Workers Face | ||
Mo | MedCity Pivot Podcast: Price Transparency is the New North in the PBM World | ||
Mo | Discover the Most Effective Aquatic Therapy Programs in Chicago Suburbs | ||
Mo | Novartis Adds to Its Immunology Prospects With Another Deal for Monte Rosa's Molecular Glue Drugs |